Dendritic Cell-Based Immunotherapy in Lung Cancer

by Dieter Stevens, Dieter Stevens, Joline Ingels, Sandra Van Lint, Sandra Van Lint, Bart Vandekerckhove, Bart Vandekerckhove, Bart Vandekerckhove, Karim Vermaelen, Karim Vermaelen, Karim Vermaelen
Published 2021-02-01

mRNA in cancer immunotherapy: beyond a source of antigen

by Lien Van Hoecke, Rein Verbeke, Heleen Dewitte, Ine Lentacker, Karim Vermaelen, Karine Breckpot, Sandra Van Lint
Published 2021-03-01

The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration

by Lien Van Hoecke, Kenny Roose, Marlies Ballegeer, Zifu Zhong, Niek N. Sanders, Stefaan De Koker, Xavier Saelens, Sandra Van Lint
Published 2020-12-01

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes

by Lien Van Hoecke, Sandra Van Lint, Kenny Roose, Alexander Van Parys, Peter Vandenabeele, Johan Grooten, Jan Tavernier, Stefaan De Koker, Xavier Saelens
Published 2018-08-01

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

by Anje Cauwels, Sandra Van Lint, Elke Rogge, Annick Verhee, Bram Van Den Eeckhout, Shengru Pang, Marco Prinz, Niko Kley, Gilles Uzé, Jan Tavernier
Published 2021-11-01

Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

by Bram Van Den Eeckhout, Leander Huyghe, Sandra Van Lint, Elianne Burg, Stéphane Plaisance, Frank Peelman, Anje Cauwels, Gilles Uzé, Niko Kley, Sarah Gerlo, Jan Tavernier
Published 2021-11-01

Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo

by Daphné Benteyn, Sébastien Anguille, Sandra Van Lint, Carlo Heirman, An MT Van Nuffel, Jurgen Corthals, Sebastian Ochsenreither, Wim Waelput, Katrien Van Beneden, Karine Breckpot, Viggo Van Tendeloo, Kris Thielemans, Aude Bonehill
Published 2013-01-01

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

by Anje Cauwels, Sandra Van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, Sarah Gerlo, José Van der Heyden, Yann Bordat, Dominiek Catteeuw, Lode De Cauwer, Elke Rogge, Annick Verhee, Gilles Uzé, Jan Tavernier
Published 2018-03-01

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

by Leander Huyghe, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uzé, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert, Jan Tavernier
Published 2020-02-01

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

by Sandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, Niels Vandamme, Stephane Plaisance, Annick Verhee, Dominiek Catteeuw, Elke Rogge, Jennifer De Geest, Nele Vanderroost, Jana Roels, Yvan Saeys, Gilles Uzé, Niko Kley, Anje Cauwels, Jan Tavernier
Published 2023-11-01